When adenovirus vectors are injected intravenously, most of the virions are quickly taken up by the reticuloendothelial system, primarily by the liver macrophages known as Kupffer cells. However, little is known about the behavior of adenovirus vectors when there is pre-existing liver disease. To study this, we examined the biodistribution of intravenously injected vector in a rat model of cirrhosis induced by bile duct ligation. Using quantitative PCR and fluorescently tagged adenovirus vectors, we observed a significant reduction in vector uptake by the cirrhotic liver and increased accumulation in the lungs. Immunocytochemistry and electron microscopy demonstrated that this was due to changes in the reticuloendothelial system, with the vector being taken up by large numbers of pulmonary intravascular macrophages in the lungs of cirrhotic rats. Interestingly, expression of vector-encoded luciferase was significantly reduced in the livers of cirrhotic rats, but was not increased in the lungs. These data demonstrate that the biodistribution of adenovirus vectors in rats is altered by cirrhosis, which suggests the possibility that these vectors might behave unexpectedly in patients with pre-existing liver conditions, particularly since pulmonary reticuloendothelial changes are known to occur in human disease.
Introduction
Adenovirus vectors are promising tools for in vivo gene delivery due to their broad tropism, but, when given by the intravascular route, their usefulness is limited by rapid macrophage-mediated clearance from the circulation. When injected into the vasculature, vectors derived from adenovirus types 2 and 5 are hepatotropic, in the sense that much of the expression from the vector is within hepatocytes. However, most of the vector is actually taken up by the reticuloendothelial system (RES) and degraded, particularly by Kupffer cells (KCs) in the liver. 1 As a result, the circulating half-life is only minutes, and opportunities to transduce other tissues are greatly reduced. 2 Indeed, it appears that there is little transduction even of hepatocytes unless the dose of adenovirus vector is high enough to first saturate the RES. 3 Uptake of adenovirus vectors by KCs also induces proinflammatory cytokines and chemokines, which contribute to the recruitment of leukocytes and subsequent liver damage. 4 Even though KCs constitute only 2.1% of the liver volume, 5 they are the major constituent of the RES. Their intrasinusoidal location provides KCs with direct access to material in the blood, and they avidly take up many different types of particles by endocytosis, phagocytosis, and pinocytosis. 6 Adenoviruses are known to bind both integrins and the coxsackie/adenovirus receptor (CAR) on many different types of cells, and they have been shown to use a V integrins to transduce KCs and other macrophages in vitro. 7 However, macrophages express minimal amounts of CAR. 8 RES activity can be altered during disease, especially during liver disease. Numerous studies in rats have shown that cirrhotic livers exhibit impaired uptake of particulates such as bacteria, microspheres, and colloidal tracers. [9] [10] [11] [12] [13] [14] However, cirrhotic rats also show greatly increased uptake of circulating particles by the lung, an organ that, in most species, is not part of the RES. [9] [10] [11] [12] [13] [14] This is due to the development of vast numbers of pulmonary intravascular macrophages (PIMs) during liver cirrhosis. 9, 10 These cells can be distinguished from alveolar and interstitial macrophages by their intravascular locationthey are attached to the endothelium and are in direct contact with plasma. PIMs are thought to derive from circulating monocytes, but the reason for their development during liver cirrhosis is unclear. It has been suggested that they may develop in response to the chronically elevated serum endotoxin levels that occur during cirrhosis, or to compensate for the substantially reduced RES activity in the cirrhotic liver. 15 We therefore postulated that changes to the RES during liver cirrhosis might lead to a shift in the biodistribution of intravenously injected adenovirus vectors, causing greater localization in the lungs. Since currently ongoing clinical trials with adenovirus vectors include patients with liver disease, it is important to note that there is extensive clinical evidence -using RES tracers such as 99m Tc-sulfur colloid -that pulmonary reticuloendothelial uptake can occur in patients with cirrhosis, mucopolysaccharidosis, hepatic allograft rejection, infection or malignancy. [16] [17] [18] [19] [20] [21] [22] [23] [24] Since the uptake of adenovirus vectors by macrophages can result in a great deal of inflammation, uptake of adenoviral vectors by PIMs in the lungs might raise the potential for unexpected pulmonary inflammation and pathology.
Results

Animal model
It has previously been shown that bile duct-ligated (BDL) rats develop cirrhosis by 4 weeks after surgery, 25 and that their lungs develop PIMs which are capable of taking up a variety of intravascular particles.
9,10 BDL rats in our experiments were jaundiced and gained weight less rapidly than controls. Upon necropsy at 4 weeks after surgery, the proximal bile duct remnant had developed into a bile-filled cyst, and the liver was enlarged and firm, with a micronodular appearance. Liver cirrhosis was confirmed histologically, with well-defined parenchymal nodules separated by fibrous septa. Large numbers of intravascular macrophages were detected in the lungs of all cirrhotic rats by immunocytochemistry, whether they received adenovirus vector or not. These PIMs were absent from the lungs of normal rats. When BDL rats were injected via the lateral tail vein with 1.2 Â 10 12 vp/kg of adenovirus vector (AdCMV-Luc) and observed for 3 days, mortality was significantly higher in the BDL group when compared to controls (BDL: 60% mortality, n¼15 versus controls: 11% mortality, n¼9; Po0.05, Fisher's exact test), with most of the deaths on the first day. This increased sensitivity of cirrhotic rats to adenovirus vector occurred even though the BDL rats received a slightly lower total dose of vector, due to an average 22% decreased weight (BDL: 236734 g versus control: 302715 g; mean7SD, Po0.0001, t-test). Elevated mortality of BDL rats after receiving adenovirus vector has previously been reported. 26 It is also worth noting that all sham or unoperated rats injected intravenously with this dose of vector showed transient signs of distress within about 10 min, including prostration, lethargia, tachypnea, and less commonly pallor or cyanosis, with the symptoms typically improving within an hour. Such symptoms were never seen after an i.v. injection of buffer. Similar symptoms have recently been reported in normal mice following i.v. injection of adenovirus vector. 27 Interestingly, the vector did not cause these transient symptoms in BDL rats. However, BDL rats were in poor health after receiving the i.v. vector and, as noted, high mortality was seen.
Adenovirus vector biodistribution
Quantitative PCR was used to examine the physical biodistribution of AdCMV-Luc after i.v. injection at a dose of 1.2 Â 10 12 vp/kg. In normal rats, the concentration of vector DNA per unit of genomic DNA was slightly higher in the liver than in the lung, although this difference was not significant (Figure 1a) . However, because livers were on average eight-fold more massive than lungs, it is clear that the total amount of vector taken up by the normal liver was much higher than the total taken up by the normal lungs. In contrast, in BDL rats, the concentration of vector DNA in the liver was significantly reduced when compared to control rats, and the concentration of vector in the lungs was significantly elevated (Figure 1a) . The vector concentration in the lungs of BDL rats was 23-fold higher than that of the , and 24 h after vector injection in BDL cirrhotic rats, or normal rats (sham or unoperated); n¼4-5 per group. Mean7SD is shown. The significance was tested by ANOVA and Tukey with *Po0.05 or **Po0.01 when compared to the corresponding control organ. In panel (c), all 6 and 24 h values were significantly (Po0.01) less than the corresponding 1 h value using the Tukey test.
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JS Smith et al cirrhotic liver. In other organs (spleen, heart, kidney, and bone marrow), relatively low vector concentrations were found, and there were no significant differences between the sham and BDL groups. We performed all experiments at 4 weeks after BDL surgery because this resulted in consistently severe cirrhosis. A preliminary experiment performed at 3 weeks after BDL surgery produced variable results -some of the rats had well-developed cirrhosis along with PIMs and robust vector uptake in their lungs, while in other rats the liver was only fibrotic, PIMs were absent, and vector uptake in liver and lungs was near-normal.
To examine whether our results were specific to the BDL model of cirrhosis, we evaluated vector biodistribution in a different model of cirrhosis, induced by chronic treatment with carbon tetrachloride (Figure 1b ). Results were similar in both models, with decreased vector uptake in the cirrhotic liver and increased uptake in the lungs. PIMs were found in the lungs of all CCl 4 cirrhotic rats (not shown).
For these PCR biodistribution studies, we harvested tissues at 1 h postinjection, because adenoviral DNA is known to be rapidly degraded in the liver. 1, 28 We performed a time-course study in the BDL model to compare degradation in the liver and lungs, as well as to discover whether there were any differences in degradation between normal and cirrhotic rats. We compared vector DNA biodistribution at 1, 6, and 24 h after i.v. injection of the vector (Figure 1c ). Degradation was extremely rapid in both lungs and liver, but this was especially pronounced in the lungs of cirrhotic BDL rats.
In order to examine the cellular distribution of the vectors, we labeled virions covalently with the fluorochrome Cy3 and injected them intravenously at a dose of 1.2 Â 10 12 vp/kg. In the livers of normal rats, fluorescent virions were concentrated almost exclusively in periportal KCs, which were positive for the macrophage marker CD163, a scavenger receptor for hemoglobin (Figure 2a , e). Smaller amounts of Cy3 vector could occasionally be found in desmin-positive stellate cells (not shown), and tiny foci were sometimes visible in hepatocytes. In other organs, Cy3-labeled vector could be seen concentrated in the marginal zones of the spleen (not shown), but none was seen in the heart or kidney of normal rats. In the lungs of normal rats, Cy3 vector was seen in small scattered deposits, but highly concentrated areas of Cy3 were not found ( Figure 2c ). Occasionally, these small Cy3 þ deposits in the normal lung were within CD163 þ monocytes or macrophages, but more often they appeared to be either intravascular or associated with capillary endothelium.
In cirrhotic BDL livers, the number of Cy3 þ cells and the intensity of Cy3 per cell were greatly reduced ( Figure  2b ). In most cirrhotic rats, only an occasional Cy3 þ cell could be found in the liver, and these were usually intrasinusoidal or intravascular CD163 þ macrophages. This reduced vector uptake in the cirrhotic liver was in spite of the observation of increased numbers of CD163 þ cells, which were enlarged and more intensely stained than in the normal liver (Figure 2a, b) . Previously, it has been found that the number of KCs increases during cirrhosis in both rats and humans, even though there is an overall reduction in liver RES function (see Discussion). In contrast to the liver, lungs from cirrhotic rats had large amounts of Cy3 vector concentrated in intravascular cells, the vast majority of which were large CD163 þ macrophages (Figure 2d , f). These PIMs were located both in capillaries and attached to the lumenal surface of larger pulmonary blood vessels, often forming aggregates that partially occluded the vessels. A similar distribution of CD163
þ PIMs was seen in cirrhotic rats that received an injection of buffer instead of vector (not shown). In the spleen, the marginal zone distribution of Cy3 vector was similar in cirrhotic and sham rats, and, in the heart and kidney, only an occasional Cy3 þ macrophage was seen. It is worth noting that the amount of Cy3 labeling required for adequate intensity in our experiments resulted in an approximately 40% reduction of infectious titer in vitro. Also, quantitative PCR results 
Adenovirus biodistribution in liver disease JS Smith et al
showed that tissue uptake of Cy3-labeled vector was lower than expected when compared to unlabeled vector, indicating that Cy3 labeling impaired vector uptake in vivo as well (not shown).
Large numbers of neutrophils were found in the lungs and liver of cirrhotic rats, including many intravascular neutrophils. This is known to be a feature of the BDL model, 10, 29 and was seen regardless of whether vector was given. As neutrophils can be phagocytic, we carefully examined whether any Cy3-labeled vector could be found in neutrophils, which were identified with an antibody against rat granulocytes (not shown). No uptake of vector by neutrophils was noted in the lungs or the liver.
To verify the cellular and subcellular localization of vector in the lungs of cirrhotic rats, unlabelled AdCMVLuc was injected intravenously into BDL rats at the same dose as before. Rats were killed at either 10 min or 1 h, and lungs were quickly fixed and processed for transmission electron microscopy. At 10 min, large numbers of virions were found in PIMs (Figure 3) . Although the vast majority of virions were found in vacuoles, we also found examples of PIMs with endocytic uptake of single virions, as well as instances of PIMs with cytoplasmic virions or perinuclear virions. PIMs with vector uptake were present in groups in larger blood vessels, as well as singly within capillaries. Virions were not seen free in the plasma or in other cell types, although rare uptake could have easily been missed. By 1 h after intravenous injection, virions were still visible in the vacuoles of PIMs using electron microscopy, but the number of virions was far fewer (not shown). This suggests that capsids rapidly dissociate or are degraded.
Distribution of expression from the vector
To determine whether the increase in vector distribution to the lungs would also be mirrored by an increase in vector transgene expression in the lungs, we examined luciferase expression in BDL rats at 3 days after injection of 1.2 Â 10 12 vp/kg of AdCMV-Luc. Although the amount of luciferase expression in the liver was significantly reduced in cirrhotic rats, we did not observe a corresponding increase in lung expression (Figure 4) . We found that luciferase expression in other organs was similar in sham and BDL rats. This is in agreement with a previous report that measured the number of cells transduced with a b-galactosidase vector, and found that cirrhotic rats show fewer transduced cells in the liver, but the number of transduced cells in other organs is not altered. 26 
Discussion
Although vector-encoded protein expression is the most important factor for therapeutic purposes, knowing the physical biodistribution of the vector is also vital for understanding the clearance of the vector, and for indicating which tissues are at risk for adverse events after gene therapy. We have shown that both the physical and the expression biodistributions are altered by liver disease. In cirrhotic rats, there was increased vector 
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JS Smith et al uptake by macrophages in the pulmonary vasculature, but this did not lead to a corresponding increase in pulmonary expression from the vector. This highlights a principle that is occasionally overlooked: the expression biodistribution can be quite different from the physical biodistribution. The physical biodistribution is important because the adenovirus capsid can, by itself, induce cytokine expression and inflammation, even without any expression of transgenes or viral genes from the vector. 30 In particular, macrophages release large amounts of cytokines after taking up adenovirus vectors. 31 Therefore, both types of biodistribution must be assessed in preclinical studies in order to judge whether a vector has the desired safety and efficacy profiles.
In both the liver and lung, we found extremely rapid degradation of the vector, indicating that only a small amount of the vector that is originally taken up by a tissue will cause productive transduction. Therefore, it is not surprising that our quantitative PCR results at 1 h postinjection and the luciferase expression at 3 days do not correlate. These two assays address the two different types of biodistribution: the PCR evaluates the initial physical distribution of the vector, and the luciferase assay reflects the eventual distribution of expression from the vector. The fact that these two distributions are so different underlines the importance of performing both types of studies. In our experiments, the unchanged luciferase expression in the lungs of cirrhotic rats demonstrates that uptake of very large amounts of vector by PIMs does not lead to a correspondingly high transgene expression. This is analogous to the situation in the normal liver, where KCs remove large amounts of vector without producing substantial amounts of expressed protein. 3 In vitro studies show that macrophages are difficult to transduce with adenovirus vectors even though they take up large amounts of vector, and intracellular trafficking of vector in macrophages is clearly different from that in other cell types. 32 We not only found increased uptake of virions in the lungs of cirrhotic rats, but also decreased liver uptake, in agreement with past studies which used a variety of other RES tracers in cirrhotic rats. [9] [10] [11] [12] [13] [14] After a substance is injected intravenously, the first capillary bed through which it passes is in the lungs, and the vigorous RES uptake in the lungs of cirrhotic rats likely explains some of the decreased uptake in the liver. In cirrhotic patients, however, decreased hepatic RES uptake is common even when pulmonary RES uptake is negligible. 33 This is in spite of the fact that KCs are enlarged and more numerous in the cirrhotic human liver. 34 The decreased hepatic RES activity in cirrhotic patients is not fully understood, but is thought to stem partly from vascular abnormalities which develop during cirrhosis, including sinusoidal capillarization, intrahepatic shunts, and shunting of blood from the portal vein to the systemic circulation, thereby bypassing hepatic sinusoids. 35, 36 In rats, similar changes in the hepatic vasculature are seen in models of cirrhosis, 35, 37 and -similar to humanshepatic RES uptake is reduced even though the KCs are enlarged and increased in number. 38, 39 At 1 h postinjection, we found that cirrhotic livers took up approximately 10-fold less vector than normal livers, but at 3 days the amount of luciferase expression was reduced by more than four orders of magnitude. As already noted, due to rapid degradation, the original quantity of vector in a tissue is an unreliable guide to the amount that causes productive transduction. Moreover, cirrhosis leads to differences in the transducibility of various cell types in the liver. In normal animals, hepatocytes are largely responsible for the high levels of expression in the liver after adenovirus gene therapy. In severely cirrhotic livers, however, there is preferential transduction of nonparenchymal cells in the fibrous septa. 40 It has been proposed that changes in the vasculature of the cirrhotic liver could contribute to this reduced transduction of hepatocytes. 26 After sinusoidal capillarization, for example, the hepatic vascular endothelium is no longer fenestrated and is surrounded by a complete basement membrane, 13 thus forming an anatomical barrier that might prevent the vector from reaching hepatocytes, while leaving endothelial and other nonparenchymal cells accessible. Additionally, both hepatocytes and nonparenchymal cells from the livers of cirrhotic rats are more difficult to transduce with adenovirus vectors in vitro. 41 Interestingly, certain species normally have large numbers of PIMs in their lungs; these include pigs, sheep, goats, cattle, horses and cats. 42, 43 As a result, in these species, the lung is a major organ for RES uptake of particulates, even though fully functional KCs are still present in the liver. In normal healthy pigs, PIMs occupy 25% of the total lung intracapillary volume. 43 Intriguingly, a systemic biodistribution study with adenovirus vector in normal pigs found localization overwhelmingly to the lungs by PCR, and pulmonary uptake was still substantial even when vector was injected directly into the portal vein to increase hepatic uptake. 44 Although a reason for this pulmonary physical biodistribution was not proposed at the time, it seems probable that this was due to the presence of PIMs in porcine lungs. It is also interesting to note that pigs react to high systemic doses of adenoviral vector with signs of respiratory distress, whether the vector is given via a peripheral vein or into the hepatic artery. 45 Pigs and sheep, in particular, are well-established models for acute respiratory distress syndrome (ARDS), and inflammatory stimuli such as endotoxin and bacteria are taken up by PIMs and cause pulmonary inflammation, edema and hemodynamic effects in these species. 46 Likewise, i.v. endotoxin causes pulmonary symptoms with high mortality in cirrhotic rats, probably due to uptake of endotoxin by PIMs and subsequent release of inflammatory mediators. 10, 15 Our future plans include analyzing cytokine expression and pathology in the lungs of cirrhotic rats after i.v. administration of adenovirus vector.
We chose to study cirrhosis models not just to examine the effect of liver cirrhosis on adenovirus vector biodistribution, but also because cirrhotic rats are excellent models for the atypical pulmonary RES uptake that has been noted in a number of human diseases. Abnormalities of the human RES have been found in numerous studies using 99m Tc-sulfur colloid or similar macrophage-tropic tracers; these clinical reports are not limited to cirrhosis and, in fact, do not always involve the liver. In patients with liver disease, inhomogeneous liver uptake of these tracers and decreased liver/spleen uptake ratios are common findings, 33 and a variable percentage of patients also have increased lung uptake, occasionally even when liver enzyme levels are within Adenovirus biodistribution in liver disease JS Smith et al normal limits. 16, 20 Pulmonary colloidal uptake is commonly seen in patients with liver cirrhosis and mucopolysaccharidosis type II. 17, 19 More rarely, it has been noted during the rejection of liver allografts, 18 trauma, 47 infection 48 and various types of malignancies, including nonhepatic malignancy. [20] [21] [22] [23] Pulmonary RES uptake has also been demonstrated in bacteremia, 24 including a direct demonstration of pulmonary clearance of bloodborne bacteria in a patient. 49 Often, the lung RES uptake disappears if the underlying disease resolves.
A subset of patients with pulmonary RES uptake also show increased bone marrow uptake of colloidal tracers, presumably by macrophages in the bone marrow. [19] [20] [21] [22] 50 It has been reported that BDL in rats can cause a slight increase in the bone marrow uptake of 99m Tc-sulfur colloid. 9 However, we did not find that cirrhosis led to any difference in bone marrow accumulation of the adenovirus vector.
Based on our findings in cirrhotic rats, it seems likely that patients with pulmonary RES activity would also have the potential for increased pulmonary clearance of intravascular adenovirus vectors. It may therefore be important to monitor clinical trials for adverse pulmonary events. Intravascular adenoviral gene therapy led to the death of a patient in a clinical trial to correct ornithine transcarbamylase deficiency, a metabolic liver disease. At autopsy, pulmonary edema and inflammation were found, and the causes of death were ARDS and multiple organ failure. 51 It is interesting to note that pathological evidences of chronic liver disease -fibrosis and steatosis -are not unusual in this patient population, and were found in a number of other patients in this trial. 52 It is unknown whether there were RES alterations in the patient who died, or whether an unusual pulmonary vector biodistribution could have played a role in the pathological sequelae.
Pulmonary RES uptake may be a risk not only when adenovirus vectors are deliberately introduced into the vasculature by intravenous or intra-arterial injection, but also when adenovirus vectors are injected into vascularized tissue or tumor, which can result in substantial spillover into the circulation. 44 Pulmonary RES uptake might also be a risk when using conditionally replicating adenoviruses, which can cause viremia. 53 As the RES plays such a major role in determining the early biodistribution of adenovirus vectors, caution may be warranted when using adenovirus vectors in patients with chronic liver disease or other conditions that may perturb the RES.
Materials and methods
Adenoviral vectors
Adenoviral vectors were replication-incompetent human serotype 5, and were deleted for E1 and E3. AdCMV-Luc contains a firefly luciferase gene driven by a CMV promoter, 54 and AdGFP (Quantum Biotechnologies Inc., Montreal, Canada) contains a green fluorescent protein gene driven by a CMV promoter. Vectors were grown on 293 cells and purified on CsCl gradients. The vector was dialyzed at 41C against two exchanges of storage buffer (2.5% glycerol, 20 mM Tris pH 8.0, 25 mM NaCl), and stored at À801C, at a concentration of approximately 1.2 Â 10 12 particles/ml. Particle concentrations were determined by absorbance at 260 nm in the presence of 0.1% sodium dodecyl sulfate (SDS). Aggregation of particles was evaluated by determining the A 320 /A 260 ratio in the absence of SDS. 55 No preparations were found to be aggregated. Infectious titers were determined by plaque assays on 293 cell monolayers. AdCMV-Luc had a particle:PFU ratio of 12. Endotoxin levels were assayed with an LAL kit and were below the lower limit of detection of 0.15 EU/ml, except for the batch of vector used in the EM and CCl 4 studies, which had an endotoxin level of 0.25 EU/ml.
Cy3 labeling of vector
CsCl-purified AdGFP was adjusted to a concentration of 1.5 Â 10 12 particles/ml and dialyzed overnight against two exchanges of PBS. A modification of the protocol of Leopold et al 56 was used. Sodium carbonate buffer (pH 9.3) was added to a final concentration of 0.05 M and the suspension was incubated with Cy3 bisfunctional dye (FluoroLink-Ab Cy3 labeling kit, Amersham Pharmacia, Piscataway, NJ) at room temperature for 30 min at 12.5% of the manufacturer's recommended concentration. The reaction was stopped by addition of 0.2% glycine, and reaction products were separated by centrifugation on a discontinuous CsCl gradient, followed by dialysis at 41C against two exchanges of storage buffer. The amount of conjugated dye was calculated as described previously. Cy3-labeled AdGFP had a dye:capsomere ratio of 3.2 and a particle:pfu ratio of 25, as compared to a particle:pfu ratio of 14 before conjugation to Cy3. Cy3-labeled vector was not aggregated, as measured by the A 320 /A 260 assay, and in preliminary experiments filtering this vector at 0.2 mm immediately before injection into rats had no effect on the biodistribution.
Animal experiments
Male Sprague-Dawley rats, 6-weeks old, were obtained from Harlan (Indianapolis, IN, USA). BDL and sham surgeries were performed on anesthetized rats by Harlan. For BDL surgery, the common bile duct was isolated, two ligatures were tied approximately 5 mm apart, and the duct was transected between the ligatures. Sham surgery involved visualizing the bile duct and then closing the incision. In biodistribution experiments, we found no differences between normal and shamoperated rats. Rats were maintained under specific pathogen-free conditions, and used for experiments at 4 weeks after surgery.
For the CCl 4 model, 6-week-old male Sprague-Dawley rats were injected subcutaneously twice weekly for 12 weeks with 4 ml/kg of a 1:1 mixture of CCl 4 and olive oil. Control rats were injected with 4 ml/kg olive oil by the same schedule.
Adenoviral vectors were administered via the lateral tail vein at a dose of 1.2 Â 10 12 particles/kg in a volume of approximately 1 ml/kg. At 5-10 min prior to killing, the animals were anesthetized with 90 mg/kg ketamine and 10 mg/kg xylazine. Organs were quickly removed. Bone marrow was flushed from tibiae with PBS, followed by one rinse.
Quantitative PCR
Frozen tissues were ground with a mortar and pestle. DNA was isolated using the DNeasyt Tissue kit (Qiagen, Valencia, CA, USA). Quantitative PCR was performed Adenovirus biodistribution in liver disease JS Smith et al using the TaqMant Universal PCR Master Mix (PE Biosystems, Branchburg, NJ, USA). The primers and fluorescent detection probe against a 98 bp region of Ad5 pIX were the same as in Einfeld et al. 57 Standard curves were generated using a plasmid containing the pIX sequences. Duplicate samples were amplified in an ABI Prism 7700 sequence detector with continuous fluorescence monitoring.
Immunocytochemistry
Lungs were inflated with 50% Tissue-Tek OCT (Sakura Finetek, Torrance, CA, USA) and 15% sucrose in PBS. Cryostat sections (10 mm) were cut and fixed in 10% buffered formalin. Sections were permeabilized with 0.1% Triton X-100t (Sigma, St Louis, MO, USA), and processed using an anti-CD163 antibody (clone ED2, Serotec, Raleigh, NC, USA) at 1.7 mg/ml, followed by a rat-absorbed anti-mouse IgG F(ab 0 ) 2 fragment conjugated to Alexa Fluor s 488 (Molecular Probes, Eugene, OR, USA). The DNA stain TO-PRO s -3 (Molecular Probes) was used at a concentration of 1 mM.
Electron microscopy
Lungs were gently inflated with 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.3, and then fixed overnight. Thin sections were cut, stained with uranyl acetate and lead citrate, and examined at 80 kV.
Luciferase activity
Frozen tissues were ground using a mortar and pestle, and lysed in lysis buffer. Protein concentrations were determined by a detergent-compatible Lowry assay. Luciferase activity was measured in duplicate using a commercial reagent (Promega, Madison, WI, USA).
